no more compounded tirzepatide Explained: Key Facts to Know Compounded Tirzepatide Weight Loss Program

FDA consumer context worth knowing: The FDA has published consumer guidance expressing concerns about unapproved GLP-1 products marketed for weight loss, including quality and dosing concerns and, in some cases, products that may use semaglutide salt forms that are not the same active ingredient as the FDA-approved reference drug

The FDA label includes warnings regarding acute pancreatitis, which has been reported in clinical trials and post-marketing surveillance

Known for her uplifting spirit and personalized approach, she meets every patient with grace, kindness, and determination to help them succeed

Severe GI events were uncommon